<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
51662-1555-1
</NDCCode>
<PackageDescription>
1 VIAL in 1 BOX (51662-1555-1) > 1 mL in 1 VIAL
</PackageDescription>
<NDC11Code>
51662-1555-01
</NDC11Code>
<ProductNDC>
51662-1555
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Hyaluronidase
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Hyaluronidase
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20210604
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
BLA
</MarketingCategoryName>
<ApplicationNumber>
BLA021859
</ApplicationNumber>
<LabelerName>
HF Acquisition Co LLC, DBA HealthFirst
</LabelerName>
<SubstanceName>
HYALURONIDASE (HUMAN RECOMBINANT)
</SubstanceName>
<StrengthNumber>
150
</StrengthNumber>
<StrengthUnit>
[USP'U]/mL
</StrengthUnit>
<Pharm_Classes>
Endoglycosidase [EPC], Glycoside Hydrolases [CS]
</Pharm_Classes>
<DEASchedule/>
<Status>
Active
</Status>
<LastUpdate>
2021-06-08
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20210604
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>